BCM
VKTX icon

Bayesian Capital Management’s Viking Therapeutics VKTX Stock Holding History

Bayesian Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,100
Closed -$633K – 537
2025
Q3 		$633K Buy
24,100
+7,900
+49% +$236K 0.13% 235
2025
Q2 		$429K Buy
+16,200
New +$426K 0.07% 317
2024
Q4 		– Sell
-4,200
Closed -$266K – 1018
2024
Q3 		$266K Buy
+4,200
New +$246K 0.03% 503
2023
Q3 		– Sell
-16,664
Closed -$270K – 1024
2023
Q2 		$270K Buy
+16,664
New +$349K 0.03% 567
2021
Q2 		– Sell
-12,800
Closed -$81K – 659
2021
Q1 		$81K Buy
+12,800
New +$90.1K 0.02% 499
2018
Q4 		– Sell
-11,600
Closed -$202K – 801
2018
Q3 		$202K Buy
+11,600
New +$138K 0.03% 566

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bayesian Capital Management's VKTX Position: Q4 2025 in Review

Bayesian Capital Management sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 24,100 shares — an estimated $633K sold.

Bayesian Capital Management first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $633K in Q3 2025. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Bayesian Capital Management reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 24,100 Viking Therapeutics shares in Q4 2025, an estimated $633K.
  • Bayesian Capital Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
  • Bayesian Capital Management's Viking Therapeutics position peaked at $633K in Q3 2025.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.